MiniMed 780GTM in children with type 1 diabetes under seven years of age: Prospective open-label, single-arm, double-center, follow-up study.

Autor:	Seget S; Department of Children's Diabetology, Medical University of Silesia, Katowice, Poland., Chobot A; Department of Pediatrics, Institute of Medical Sciences, University of Opole, Opole, Poland., Rusak E; Department of Children's Diabetology, Medical University of Silesia, Katowice, Poland., Ochab A; Department of Pediatrics, Institute of Medical Sciences, University of Opole, Opole, Poland., Bielawska A; Department of Children's Diabetology, Medical University of Silesia, Katowice, Poland., Polanska J; Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland., Jarosz-Chobot P; Department of Children's Diabetology, Medical University of Silesia, Katowice, Poland.
Jazyk:	angličtina
Zdroj:	Technology and health care : official journal of the European Society for Engineering and Medicine [Technol Health Care] 2024; Vol. 32 (3), pp. 1463-1472.
DOI:	10.3233/THC-230490
Abstrakt:	Background: Given the steadily rising incidence of type 1 diabetes (T1D), particularly among the youngest preschool children, coupled with well-documented challenges of achieving and maintaining optimal metabolic control in this age group, there is a growing need for advanced technological devices. Objective: To evaluate glycaemic control in children below the age of seven with type 1 diabetes (T1D) and assess the safety of the advanced hybrid closed loop (AHCL) system in comparison to the previous treatment method, a sensor-augmented pump with predictive low-glucose suspend (SAP-PLGS). Method: Data from 10 children (aged 2.60-6.98 years) with T1D who transitioned to the AHCL system from SAP-PLGS were analysed. SAP-PLGS records from two weeks prior to the initiation of AHCL were compared with records from the initial four weeks post-switch (excluding the training period). These data were examined at two 2-week intervals and compared with records from two weeks post six-month usage of the AHCL. Results: A significant decrease in the average nighttime glucose concentration was observed compared to pre-AHCL values (p= 0.001, concordance W = 0.53). The Glucose Management Indicator (GMI) value significantly decreased from 6.88 ± 0.37% to 6.52 ± 0.32% (p= 0.018, rbc = 0.93) immediately following the device switch and stabilized at 6.50 ± 0.28% (p= 0.001, W = 0.53) and 6.55 ± 0.41% (p= 0.001, W = 0.53) at subsequent stages of the study. An improvement was also observed in mean glucose values for time spent < 54 mg/dl, while the proportion of time within this range was maintained, both during the day (p< 0.001, W = 0.58) and at night (p= 0.002, W = 0.83). Conclusion: The AHCL MiniMed 780GTM system improved glycaemic control in the studied group of children under seven years of age with T1D compared to previous SAP-PLGS therapy. It proved to be safe for delivering insulin in this age group.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu